FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 652 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO... September 18, 2021 10 Tips for National Cancer Prevention Month February 10, 2021 Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... June 2, 2021 Snowboarder Wins Gold Medal At Winter Olympics After Beating Cancer February 8, 2022 Load more HOT NEWS News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... Talking About Your Sexual Orientation and Gender Identity With Your Cancer... How to Talk About Cancer With Someone Who Has It Cleveland Clinic Launches Breast Cancer Vaccine Trial
